反应详情

To a solution of 5-(((1-(tetrahydro-2H-pyran-2-yl)-3-(trifluoromethyl)-1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (0.03 g, 0.054 mmol) in DCM (5 mL) at 0° C., TFA (2 mL, 26.0 mmol) was added. The reaction mixture was stirred at room temperature for 5 h. Solvent was removed under vacuum and the crude product was purified by preparative HPLC on an Inertsil ODS column (19×250 mm, 5μ) using 0-65% mobile phase B (ACN) in mobile phase A (0.1% TFA) over 6 min to give N-(4-(trifluoromethoxy)phenyl)-5-(((3-(trifluoromethyl)-1H-indazol-5-yl)oxy)methyl)pyrimidin-2-amine as an off-white solid (10 mg, 39%). 1HNMR 400 MHz, DMSO-d6: δ ppm 5.11 (s, 1H), 7.22-7.22 (m, 1H), 7.29-7.30 (m, 3H), 7.65 (d, J=9.20 Hz, 1H), 7.86-7.87 (m, 2H), 8.67 (s, 2H), 10.00 (s, 1H), 13.90-0.00 (m, 1H). LCMS: R.T.=2.13 min; [M+H]+=468.0.

1. customSolvent was removed under vacuum
2. customthe crude product was purified by preparative HPLC on an Inertsil ODS column (19×250 mm, 5μ)
3. customover 6 min